Biomerica, Inc. reported its financial results for Fiscal 2025, showing a net sales of $5.3 million, a slight decrease from the previous year. Despite global economic uncertainties affecting sales, the company achieved a $1.3 million reduction in operating expenses, leading to an improved operating loss of $5.1 million, a 19% improvement from the prior year. The company also saw an increase in international sales, although gross profit decreased to $498,000. Cash used in operating activities decreased to $3.8 million, demonstrating stronger operating discipline. Operating expenses were reduced by more than $1.3 million, with selling, general, and administrative expenses at $4.6 million, and research and development expenses at $1.0 million. These cost reductions contributed to the improvement in operating loss, despite revenue challenges. Overall, Biomerica showed resilient portfolio performance amidst economic uncertainties.